Doç. Dr. Erkan Kayıkçıoğlu — Tıbbi Onkoloji & Akciğer Kanseri
erkankayikcioglu.com
LaunchIndex first observed Doç. Dr. Erkan Kayıkçıoğlu — Tıbbi Onkoloji & Akciğer Kanseri (erkankayikcioglu.com) live on 11 November 2026. View its launch screenshot, category, and verification evidence.
A launch record built from evidence.
Doç. Dr. Erkan Kayıkçıoğlu — Tıbbi Onkoloji & Akciğer Kanseri (erkankayikcioglu.com) was first observed live on 11 November 2026.
Profile of Doç. Dr. Erkan Kayıkçıoğlu, medical oncologist specializing in lung and prostate cancer; highlights multidisciplinary care, clinical trials, and patient information with contact and appointment details.
Its profile is classified as Professional service within Health / Health and wellness.
What the launch signal contained.
- First observed live
- Previous state
- No prior non-live observation
- Last verified
- Canonical host
- www.erkankayikcioglu.com
- Category
- Health / Health and wellness
- Website type
- Professional service
- Observed title
- Doç. Dr. Erkan Kayıkçıoğlu — Tıbbi Onkoloji & Akciğer Kanseri
- Observed description
- Doç. Dr. Erkan Kayıkçıoğlu — Tıbbi Onkoloji uzmanı. Akciğer ve prostat kanseri başta olmak üzere solid organ kanserleri; İSÜ Liv Hospital Bahçeşehir'de Faz 2 ve Faz 3 klinik araştırmalarda sorumlu araştırmacı (PI).
- Detected technologies
- None detected
- Screenshot captured
- Evidence source
- Browser observation · Local
- Evidence confidence
- 93%
- HTTP status
- 200
A canonical launch profile for erkankayikcioglu.com.
Share the profile directly or add the optional badge to the website. A badge is never required for inclusion, verification, or ranking.
Is this your website?
Claim this profile to add verified owner information.
What do you make of this launch?
Vote on the site and leave a short note for other people exploring the new web.
Report an issueFlag spam, illegal or harmful content, or inaccurate information.
Reports are private and reviewed by the moderation team. No sign-in is required, so this report will be anonymous.
Join the discussion
Sign in with Google to vote or comment.
Sign in to participateComments
0 commentsBe the first to leave a useful observation.